Avacta Group (AVCT)
AVCT Share PerformanceMore
|52 week high||134.30 06/01/16|
|52 week low||78.00 30/11/16|
|52 week change||-54.50 (-40.52%)|
|4 week volume||395,608 07/11/16|
Media for (AVCT)
Latest News« previous» nextMore
01/12/2016 - 07:00 RNS
RNS Number: 5612Q Avacta Group PLC 01 December 2016 1 December 2016 Avacta Group plc ("Avacta" or "the Group" or "the Company") Notice of AGM, posting of accounts and Directorate change Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, confirms that the Annual Report and Accounts for the year ended ...
23/11/2016 - 07:38 StockMarketWire
Avacta Group will present data that highlights the competitive performance of Affimers in affinity separation application...
23/11/2016 - 07:00 RNS
RNS Number: 8848P Avacta Group PLC 23 November 2016 23 November 2016 Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta demonstrates key performance benefits of Affimer technology for affinity separation Avacta to present Affimer performance data at bioProcessUK, 23-24 November. Affimer technology shown to offer key perfor...
07/11/2016 - 09:02 StockMarketWire
Avacta Group, the developer of Affimer biotherapeutics and research reagents, has appointed Professor Gerard Evan, FRS...
07/11/2016 - 07:00 RNS
RNS Number: 4136O Avacta Group PLC 07 November 2016 7 November 2016 Avacta Group plc ("Avacta" or "the Group" or "the Company") World-leading cancer stem cell expert joins Avacta Scientific Advisory Board Appointment of Professor Gerard Evan further supports Affimer immuno-oncology therapeutics programme Avacta Group plc (AIM: AVCT), th...
02/11/2016 - 07:40 StockMarketWire
Avacta Group has announced a research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to evaluate th...
02/11/2016 - 07:00 RNS
RNS Number: 0361O Avacta Group PLC 02 November 2016 02 November 2016 Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta announces CAR-T cell therapy research collaboration with major US cancer centre CAR-T cell therapy is a major new area of cancer therapy that has attracted $billions of investment in the past few years Affimer ...
01/11/2016 - 08:16 StockMarketWire
Avacta Group will present detailed data from the first pre-clinical in-vivo studies of its therapeutic Affimer platform at P...
|Dividend yield||0 %|
Equity Research (AVCT)
Avacta Group Plc
Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody...
Avacta Group Plc
Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a revolutionary alternative to the...
Avacta Group Plc
Avacta is a life science company providing high quality and highly specific tools to the biopharmaceutical industry to help in the diagnosis and treatment of humans and animals. The group’s Affimer...
- 1 of 4
Latest discussion posts More
“Thanks Mol Your comments much appreciated. I was impressed by the report too, and couldn't understand why such a step drop would occur. As you say, it is only ...”▼
“Year end 2016 2015 Share Capital 6,915 5,057 Share premium 621 35,756 Capital reserve ...”▼
“nothing again especially having checked lse and advfn boards just now lol :) mol”▼
Codes & Symbols
|Symbols||AVCT, LSE:AVCT, AVCT.L, AVCT:LN, LON:AVCT, XLON:AVCT|